A1 Refereed original research article in a scientific journal
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance
Authors: Katherine Johnson, Peter J Leary, Olivier Govaere, Matthew J Barter, Sarah H Charlton, Simon J Cockell, Dina Tiniakos, Michalina Zatorska, Pierre Bedossa, M Julia Brosnan, Jeremy F Cobbold, Mattias Ekstedt, Guruprasad P Aithal, Karine Clément, Jörn M Schattenberg, Jerome Boursier, Vlad Ratziu, Elisabetta Bugianesi, Quentin M Anstee, Ann K Daly, on behalf of the
LITMUS Consortium Investigators,
James Clark, Heather J Cordell, Rebecca Darlay, Christopher P Day, Tim Hardy, Yang-Lin Liu, Fiona Oakley, Jeremy Palmer, Rachel Queen, Kristy Wonders, Patrick M Bossuyt, Adriaan G Holleboom, Hadi Zafarmand, Yasaman Vali, Jenny Lee, Karine Clement, Raluca Pais, Detlef Schuppan, Michael Allison, Sergio Rodriguez Cuenca, Vanessa Pellegrinelli, Michele Vacca, Antonio Vidal-Puig, Tuulia Hyötyläinen, Aidan McGlinchey, Matej Orešič, Partho Sen, Jose Mato, Óscar Millet, Jean-Francois Dufour, Stephen Harrison, Stefan Neubauer, Michael Pavlides, Ferenc Mozes, Salma Akhtar, Rajarshi Banerjee, Matt Kelly, Elizabeth Shumbayawonda, Andrea Dennis, Charlotte Erpicum, Manuel Romero-Gomez, Rocío Gallego-Durán, Isabel Fernández, Morten Karsdal, Diana Leeming, Mette Juul Fisker, Elisabeth Erhardtsen, Daniel Rasmussen, Per Qvist, Antonia Sinisi, Estelle Sandt, Maria Manuela Tonini, Maurizio Parola, Chiara Rosso, Fabio Marra, Amalia Gastaldelli, Sven Francque, Stergios Kechagias, Hannele Yki-Järvinen, Kimmo Porthan, Saskia van Mil, George Papatheodoridis, Helena Cortez-Pinto, Luca Valenti, Salvatore Petta, Luca Miele, Andreas Geier, Christian Trautwein, Paul Hockings, Phil Newsome, David Wenn, Cecília Maria Pereira Rodrigues, Rémy Hanf, Pierre Chaumat, Christian Rosenquist, Aldo Trylesinski, Pablo Ortiz, Kevin Duffin, Carla Yunis, Melissa Miller, Theresa Tuthill, Judith Ertle, Ramy Younes, Leigh Alexander, Rachel Ostroff, Mette Skalshøi Kjær, Lars Friis Mikkelsen, Clifford Brass, Lori Jennings, Maria-Magdalena Balp, Miljen Martic, Guido Hanauer, Sudha Shankar, Richard Torstenson, Céline Fournier, Richard Ehman, Michael Kalutkiewicz, Kay Pepin, Joel Myers, Diane Shevell, Gideon Ho, Henrik Landgren, Rob Myers, Lynda Doward, Diane Whalley, James Twiss
Publisher: Elsevier
Publication year: 2022
Journal: JHEP Reports
Journal acronym: JHEP Reports
Volume: 4
Issue: 2
First page : 100409
eISSN: 2589-5559
DOI: https://doi.org/10.1016/j.jhepr.2021.100409
Web address : https://www.sciencedirect.com/science/article/pii/S2589555921001853
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/175843189
Background & Aims
Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages.
Methods
We profiled 2,083 serum miRNAs in a discovery cohort (183 cases with NAFLD representing the complete NAFLD spectrum and 10 population controls). miRNA libraries generated by HTG EdgeSeq were sequenced by Illumina NextSeq. Selected serum miRNAs were profiled in 372 additional cases with NAFLD and 15 population controls by quantitative reverse transcriptase PCR.
Results
Levels of 275 miRNAs differed between cases and population controls. Fewer differences were seen within individual NAFLD stages, but miR-193a-5p consistently showed increased levels in all comparisons. Relative to NAFL/non-alcoholic steatohepatitis (NASH) with mild fibrosis (stage 0/1), 3 miRNAs (miR-193a-5p, miR-378d, and miR378d) were increased in cases with NASH and clinically significant fibrosis (stages 2–4), 7 (miR193a-5p, miR-378d, miR-378e, miR-320b, miR-320c, miR-320d, and miR-320e) increased in cases with NAFLD activity score (NAS) 5–8 compared with lower NAS, and 3 (miR-193a-5p, miR-378d, and miR-378e) increased but 1 (miR-19b-3p) decreased in steatosis, activity, and fibrosis (SAF) activity score 2–4 compared with lower SAF activity. The significant findings for miR-193a-5p were replicated in the additional cohort with NAFLD. Studies in Hep G2 cells showed that following palmitic acid treatment, miR-193a-5p expression decreased significantly. Gene targets for miR-193a-5p were investigated in liver RNAseq data for a case subgroup (n = 80); liver GPX8 levels correlated positively with serum miR-193a-5p.
Conclusions
Serum miR-193a-5p levels correlate strongly with NAFLD activity grade and fibrosis stage. MiR-193a-5p may have a role in the hepatic response to oxidative stress and is a potential clinically tractable circulating biomarker for progressive NAFLD.
Downloadable publication This is an electronic reprint of the original article. |  |
